trimetrexate and Esophageal Neoplasms studies

trimetrexate and Esophageal Neoplasms

Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.

Esophageal Neoplasms: Tumors or cancer of the ESOPHAGUS.

Research Excerpts

Excerpt	Relevance	Reference
"Trimetrexate (TMQ) is a synthetic folate antagonist that has demonstrated non-cross resistance with methotrexate in preclinical screens."	2.68	Phase II trial of trimetrexate in advanced esophageal cancer: a southwest oncology group study. ( Brown, TD; Fleming, TR; Macdonald, JS; Ross, SW, 1996)

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (25.00)	18.7374
1990's	3 (75.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Timeframe

Studies, this research(%)

All Research%

pre-1990

1 (25.00)

18.7374

1990's

3 (75.00)

18.2507

2000's

0 (0.00)

29.6817

2010's

0 (0.00)

24.3611

2020's

0 (0.00)

2.80

Authors

Authors	Studies
Fleming, TR	1
Brown, TD	1
Ross, SW	1
Macdonald, JS	1
Haller, DG	2
Falkson, G	2
Ryan, LM	1
Alberts, AS	1
Badata, M	1
Terblanche, AP	1
Schmid, EU	1

Studies

Fleming, TR

Brown, TD

Ross, SW

Macdonald, JS

Haller, DG

Falkson, G

Ryan, LM

Alberts, AS

Badata, M

Terblanche, AP

Schmid, EU

Reviews

1 review available for trimetrexate and Esophageal Neoplasms

Article	Year
Trimetrexate: experience with solid tumors. Seminars in oncology, 1997, Volume: 24, Issue:5 Suppl 18 Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials a	1997

Article

Year

Trimetrexate: experience with solid tumors.

Seminars in oncology, 1997, Volume: 24, Issue:5 Suppl 18

Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials a

1997

Trials

2 trials available for trimetrexate and Esophageal Neoplasms

Article	Year
Phase II trial of trimetrexate in advanced esophageal cancer: a southwest oncology group study. Investigational new drugs, 1996, Volume: 13, Issue:4 Topics: Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Drug Administration Schedule; Esophageal	1996
Phase II trial for the evaluation of trimetrexate in patients with inoperable squamous carcinoma of the esophagus. American journal of clinical oncology, 1992, Volume: 15, Issue:5 Topics: Aged; Carcinoma, Squamous Cell; Drug Evaluation; Esophageal Neoplasms; Female; Humans; Male; Middle	1992

Article

Year

Phase II trial of trimetrexate in advanced esophageal cancer: a southwest oncology group study.

Investigational new drugs, 1996, Volume: 13, Issue:4

Topics: Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Drug Administration Schedule; Esophageal

1996

Phase II trial for the evaluation of trimetrexate in patients with inoperable squamous carcinoma of the esophagus.

American journal of clinical oncology, 1992, Volume: 15, Issue:5

Topics: Aged; Carcinoma, Squamous Cell; Drug Evaluation; Esophageal Neoplasms; Female; Humans; Male; Middle

1992

Other Studies

1 other study available for trimetrexate and Esophageal Neoplasms

Article	Year
Trimetrexate in advanced carcinoma of the esophagus. Investigational new drugs, 1988, Volume: 6, Issue:4 Topics: Carcinoma, Squamous Cell; Drug Evaluation; Esophageal Neoplasms; Humans; Quinazolines; Trimetrexate	1988

Article

Year

Trimetrexate in advanced carcinoma of the esophagus.

Investigational new drugs, 1988, Volume: 6, Issue:4

Topics: Carcinoma, Squamous Cell; Drug Evaluation; Esophageal Neoplasms; Humans; Quinazolines; Trimetrexate

1988